SGLT2 inhibitors have shown great promise in the management of diabetes mellitus and the prevention of cardiovascular complications, but increasing evidence suggests that their use can be associated with an increased risk of acute kidney injury. Insights into the mechanisms involved might help to identify individuals who are at risk of renal injury.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The safety of SGLT-2 inhibitors in diabetic patients submitted to elective percutaneous coronary intervention regarding kidney function: SAFE-PCI pilot study
Diabetology & Metabolic Syndrome Open Access 26 June 2023
-
Sodium glucose co-transporter-2 inhibitors in intensive care unit patients with type 2 diabetes: a pilot case control study
Critical Care Open Access 16 May 2023
-
Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review
Diabetes Therapy Open Access 26 October 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Skrtic, M. et al. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia 57, 2599–2602 (2014).
Zinman, B., Lachin, J. M. & Inzucchi, S. E. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2016).
Wanner, C. et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375, 323–334 (2016).
Hahn, K., Kanbay, M., Lanaspa, M. A., Johnson, R. J. & Ejaz, A. A. Serum uric acid and acute kidney injury: a mini review. J. Advanced Research (in press).
Bjornstad, P. et al. Fructose and uric acid in diabetic nephropathy. Diabetologia 58, 1993–2002 (2015).
Kitamura, H. et al. Inhibition of myo-inositol transport causes acute renal failure with selective medullary injury in the rat. Kidney Int. 53, 146–153 (1998).
Acknowledgements
This work is supported by NIH grants DK109408-01A1 (to R.J.J.) and DK108859-01 (to M.A.L.)
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R.J.J. and M.A.L. have patents and patent applications related to blocking fructose metabolism, and are members of Colorado Research Partners, which is a startup company that is attempting to make inhibitors of fructose metabolism. R.J.J. is also on the Scientific Board of XORT Therapeutics and Amway. The other authors declare no competing interests.
PowerPoint slides
Related links
Rights and permissions
About this article
Cite this article
Hahn, K., Ejaz, A., Kanbay, M. et al. Acute kidney injury from SGLT2 inhibitors: potential mechanisms. Nat Rev Nephrol 12, 711–712 (2016). https://doi.org/10.1038/nrneph.2016.159
Published:
Issue date:
DOI: https://doi.org/10.1038/nrneph.2016.159
This article is cited by
-
Sodium glucose co-transporter-2 inhibitors in intensive care unit patients with type 2 diabetes: a pilot case control study
Critical Care (2023)
-
The safety of SGLT-2 inhibitors in diabetic patients submitted to elective percutaneous coronary intervention regarding kidney function: SAFE-PCI pilot study
Diabetology & Metabolic Syndrome (2023)
-
Is there any robust evidence showing that SGLT2 inhibitor use predisposes to acute kidney injury?
Journal of Nephrology (2022)
-
The role of body mass index on IgA nephropathy prognosis: a systematic review and meta-analysis
International Urology and Nephrology (2022)
-
Acute kidney injury following SGLT2 inhibitors among diabetic patients: a pharmacovigilance study
International Urology and Nephrology (2022)
